Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 200...(tinued to outperform our target of 25%an...),Health

Date:6/23/2008

tinued to outperform our target of 25% annual growth, which we provided at the start of this fiscal year. We completed the sale of our Endovascular business in the fourth quarter and are looking forward to a successful strategic relationship with Spectranetics."

First Quarter Fiscal 2009

For the first quarter of fiscal year 2009, the Company believes that its net sales will be in the range of $13.0 to $13.4 million, representing a 13% to 16% increase from the prior year period. Royalties are expected to be in the range of $6.4 to $6.5 million, a 5% to 7% increase from the prior year period. Total revenues are anticipated to be in the range of $19.4 to $19.9 million, a 10% to 13% increase from the prior year period.

The Company expects fiscal 2009 first quarter diluted earnings per share of $0.34 to $0.36 per share, an increase of 113% to 125% compared to adjusted diluted earnings per share of $0.16 for the same period in fiscal year 2008. Adjusted diluted earnings per share for the first quarter of fiscal year 2008 exclude after-tax charges of $2.2 million, or $0.17 per share, for the acceleration of stock awards and discontinuation of the Company's embolic protection platform. Including these items, the 2008 first quarter reported diluted loss per share was ($0.02).

Fiscal Year 2009

The Company believes total revenues for fiscal year 2009 will be in a range of $86.7 to $89.0 million, which would represent growth of approximately 10% to 12% over estimated fiscal 2008 total revenues, and that net sales will be in the range of $58.0 to $60.0 million. The Company anticipates fiscal 2009 royalty income in a range of $27.5 to $28.0 million.

Joe Kaufmann noted, "We will continue to invest in research and development to drive future revenue growth, with total research and development spending for fiscal 2009 estimated to be $21.0 million. Approximately 60% of this funding will be dedicated to the biomaterials side of our business t
'/>"/>

SOURCE Kensey Nash Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Announces $25 Million Stock Repurchase Program
3. Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
4. Kensey Nash Reports First Quarter Fiscal Year 2008 Results
5. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
6. Kensey Nash to Present at the 19th Annual Piper Jaffray Health Care Conference
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
9. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
10. Kensey Nash Reports Third Quarter Record Revenue and Sales
11. Kensey Nash to Present at the Bank of America 2008 Health Care Conference